glp-1 microbiome Effects of receptor agonist on changes in the gut bacterium and the underlying mechanisms GLP-1 Medicines And Gut Bacterial

Additionally, a weight loss of more than 25% was achieved in 40.4% of patients receiving CagriSema, compared to 16.2% of patients receiving semaglutide 2.4 mg, 6% of patients receiving cagrilintide 2.4 mg and 0.9% of patients receiving placebo

But anyone marketing it as a proven enhancement to tirzepatide efficacy is getting ahead of the science

But as dual agonists entered the scene, researchers began to appreciate GIPs enhancing role in synergy with GLP-1

If levels are inadequate, the use of fats as an energy source can be affected and fatigue , reduced exercise tolerance or slower recovery may occur

JMCP, 2024, Vol 30(8), pp 860867

With the market projected to grow in the coming years, driven by the increasing prevalence of these conditions, pharmaceutical companies have been investing heavily in developing and marketing GLP-1 agonists